Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Christopher Goetz and Paul Carvey.
Christopher Goetz
Connection Strength
0.907
Paul Carvey
  1. Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology. 1998 Feb; 50(2):515-7.
    View in: PubMed
    Score: 0.156
  2. Animal models of tardive dyskinesia: their use in the search for new treatment methods. Mod Probl Pharmacopsychiatry. 1983; 21:5-20.
    View in: PubMed
    Score: 0.055
  3. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology. 2002 May 14; 58(9):1418-22.
    View in: PubMed
    Score: 0.052
  4. The role of the serotonin system in animal models of myoclonus. Adv Neurol. 2002; 89:244-8.
    View in: PubMed
    Score: 0.051
  5. Posthypoxic myoclonus in the rat: natural history, stability, and serotonergic influences. Mov Disord. 2000; 15 Suppl 1:39-46.
    View in: PubMed
    Score: 0.044
  6. Animal model of posthypoxic myoclonus: effects of serotonergic antagonists. Neurology. 1999 Jan 01; 52(1):16-21.
    View in: PubMed
    Score: 0.042
  7. 5-Hydroxytryptophan-induced myoclonus in guinea pigs: mediation through 5-HT1/2 receptor subtypes. Eur J Pharmacol. 1998 Apr 17; 347(1):51-6.
    View in: PubMed
    Score: 0.040
  8. The stability of carbidopa in solution. Mov Disord. 1997 Jul; 12(4):608-10.
    View in: PubMed
    Score: 0.037
  9. Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation. Neurology. 1996 Dec; 47(6):1493-5.
    View in: PubMed
    Score: 0.036
  10. Alpha-tocopherol in the ventricular cerebrospinal fluid of Parkinson's disease patients: dose-response study and correlations with plasma levels. Neurology. 1996 Oct; 47(4):1037-42.
    View in: PubMed
    Score: 0.036
  11. Levodopa stability in solution: time course, environmental effects, and practical recommendations for clinical use. Mov Disord. 1996 Jan; 11(1):24-6.
    View in: PubMed
    Score: 0.034
  12. Blood levodopa levels and unified Parkinson's disease rating scale function: with and without exercise. Neurology. 1993 May; 43(5):1040-2.
    View in: PubMed
    Score: 0.028
  13. Striatal extracts from patients with Parkinson's disease promote dopamine neuron growth in mesencephalic cultures. Exp Neurol. 1993 Mar; 120(1):149-52.
    View in: PubMed
    Score: 0.028
  14. Levodopa reduces the growth promoting effects of striatal extracts on rostral mesencephalic tegmentum cultures. Exp Neurol. 1991 Oct; 114(1):28-34.
    View in: PubMed
    Score: 0.025
  15. The potential use of a dopamine neuron antibody and a striatal-derived neurotrophic factor as diagnostic markers in Parkinson's disease. Neurology. 1991 May; 41(5 Suppl 2):53-8; discussion 59-60.
    View in: PubMed
    Score: 0.024
  16. Disappearance of a putative DA-neuron antibody following adrenal medulla transplantation: relationship to a striatal-derived DA neuron trophic factor. Prog Brain Res. 1990; 82:693-7.
    View in: PubMed
    Score: 0.022
  17. An antibody in the CSF of Parkinson's disease patients disappears following adrenal medulla transplantation. Neurosci Lett. 1988 Nov 22; 94(1-2):192-7.
    View in: PubMed
    Score: 0.021
  18. Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations. Neurology. 1988 Jul; 38(7):1143-6.
    View in: PubMed
    Score: 0.020
  19. Concurrent treatment with benztropine and haloperidol attenuates development of behavioral hypersensitivity but not dopamine receptor proliferation. Life Sci. 1988; 42(22):2207-15.
    View in: PubMed
    Score: 0.019
  20. The effect of thioridazine on haloperidol induced behavioral hypersensitivity. Life Sci. 1986 May 12; 38(19):1707-14.
    View in: PubMed
    Score: 0.017
  21. The effect of antimuscarinic agents on haloperidol induced behavioral hypersensitivity. Eur J Pharmacol. 1986 Jan 21; 120(2):193-9.
    View in: PubMed
    Score: 0.017
  22. Drug-induced myoclonus. Adv Neurol. 1986; 43:251-64.
    View in: PubMed
    Score: 0.017
  23. L-5-HTP-induced myoclonic jumping behavior in guinea pigs: an update. Adv Neurol. 1986; 43:509-17.
    View in: PubMed
    Score: 0.017
  24. The pathophysiology of tardive dyskinesia. J Clin Psychiatry. 1985 Apr; 46(4 Pt 2):38-41.
    View in: PubMed
    Score: 0.016
  25. Neuroleptic-induced dopamine hyposensitivity. Life Sci. 1984 Apr 09; 34(15):1475-9.
    View in: PubMed
    Score: 0.015
  26. Animal models of tardive dyskinesias. Clin Neuropharmacol. 1983 Jun; 6(2):129-35.
    View in: PubMed
    Score: 0.014
  27. Estrogen supplementation in the posthypoxic myoclonus rat model. Clin Neuropharmacol. 2001 Jan-Feb; 24(1):58-61.
    View in: PubMed
    Score: 0.012
  28. Clinical improvement in parkinsonian patients undergoing adrenal to caudate transplantation is not reflected by chromogranin A or basic fibroblast growth factor in ventricular fluid. Exp Neurol. 1991 Mar; 111(3):276-81.
    View in: PubMed
    Score: 0.006
  29. Effect of chronic levodopa on haloperidol-induced behavioral supersensitivity in the guinea pig. Adv Neurol. 1982; 35:213-9.
    View in: PubMed
    Score: 0.003
  30. The effect of chronic levodopa on haloperidol induced behavioral supersensitivity in the guinea pig. Life Sci. 1981 May 11; 28(19):2173-8.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.